You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
永泰生物-B(06978.HK)2024年度虧損1.87億元 同比收窄44.18%
格隆匯 03-31 23:36

格隆匯3月31日丨永泰生物-B(06978.HK)公佈年度業績,截至2024年12月31日止年度,集團其他收入爲人民幣3378.8萬元,同比增長220.36%;公司擁有人應佔年內虧損爲人民幣1.87億元,同比收窄44.18%;基本每股虧損爲人民幣0.36元。

集團的研發開支由截至2023年12月31日止年度約人民幣1.77億元減少約13.0%至截至2024年12月31日止年度約人民幣1.54億元,主要是由於研發項目材料、折舊及攤銷增加,部分被訂約成本減少和員工成本減少所抵銷。

銀行結餘及現金由2023年12月31日約人民幣5220萬元減少約人民幣520萬元至2024年12月31日約人民幣4700萬元,主要是由於研發耗用現金所致。

集團選擇了預防肝癌術後復發作爲EAL®臨牀試驗的臨牀適應症。於公告日期,集團核心候選產品EAL®的附條件新藥上市申請("NDA")已獲得中國國家藥品監督管理局("NMPA")藥品審評中心("CDE")的受理。集團產品管線覆蓋非基因改造及基因改造產品,以及多靶點及單靶點產品等主要類別的細胞免疫治療產品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account